Immunology of age-related macular degeneration
Reads0
Chats0
TLDR
The diverse immune cell types, inflammatory activators and pathways that are involved in AMD pathogenesis are outlined and the future of inflammation-directed therapeutics to treat AMD in the growing aged population is discussed.Citations
More filters
Journal ArticleDOI
The Continuum of Aging and Age-Related Diseases: Common Mechanisms but Different Rates.
Claudio Franceschi,Paolo Garagnani,Cristina Morsiani,Maria Conte,Aurelia Santoro,Andrea Grignolio,Daniela Monti,Miriam Capri,Stefano Salvioli +8 more
TL;DR: The hypothesis that ARDs and GSs such as frailty can be conceptualized as accelerated aging will be discussed, and the use of DNA methylation, N-glycans profiling, and gut microbiota composition to complement the available disease-specific markers are proposed.
Journal ArticleDOI
Inflammation and its role in age-related macular degeneration
TL;DR: Elevations in levels of local and systemic biomarkers indicate that chronic inflammation is involved in the pathogenesis of both disease forms of age-related macular degeneration.
Journal ArticleDOI
Efficacy and Safety of Lampalizumab for Geographic Atrophy Due to Age-Related Macular Degeneration: Chroma and Spectri Phase 3 Randomized Clinical Trials.
Frank G. Holz,Srinivas R. Sadda,Brandon G. Busbee,Emily Y. Chew,Paul Mitchell,Adnan Tufail,Christopher Brittain,Daniela Ferrara,Sarah Gray,Lee Honigberg,Jillian Martin,Barbara Tong,Jason S. Ehrlich,Neil M. Bressler +13 more
TL;DR: In Chroma and Spectri, the largest studies of GA conducted to date, lampalizumab did not reduce GA enlargement vs sham during 48 weeks of treatment, and no benefit was observed across prespecified subgroups, including by complement factor I–profile biomarker.
Journal ArticleDOI
Immune complement and coagulation dysfunction in adverse outcomes of SARS-CoV-2 infection.
Vijendra Ramlall,Phyllis M. Thangaraj,Cem Meydan,Cem Meydan,Jonathan Foox,Daniel Butler,Jacob Kim,Ben May,Jessica K De Freitas,Benjamin S. Glicksberg,Christopher E. Mason,Nicholas P. Tatonetti,Sagi Shapira +12 more
TL;DR: A combination of clinical and molecular analyses supports an association between disorders of immune complement or coagulation with poor outcome in patients with SARS-CoV-2 infection.
Journal ArticleDOI
Parainflammation, chronic inflammation, and age-related macular degeneration
TL;DR: The basic principles of retinal innate‐immune responses to endogenous chronic insults in normal aging and in age-related macular degeneration are discussed and the difference between beneficial parainflammation and the detrimental chronic inflammation is explored in the context of age‐related macularity degeneration.
References
More filters
Journal Article
The pilot study.
TL;DR: A randomized controlled experiment is designed to test whether access to affordable day care (in the form of subsidies, for example) would incentivize Saudi mothers to search actively for employment and to remain employed once they are hired.
Journal ArticleDOI
Ranibizumab for Neovascular Age-Related Macular Degeneration
Philip J. Rosenfeld,David M. Brown,Jeffrey S. Heier,David S. Boyer,Peter K. Kaiser,Carol Chung,Robert Y. Kim +6 more
TL;DR: Intravitreal administration of ranibizumab for 2 years prevented vision loss and improved mean visual acuity, with low rates of serious adverse events, in patients with minimally classic or occult (with no classic lesions) choroidal neovascularization secondary to age-related macular degeneration.
Journal ArticleDOI
Complement Factor H Polymorphism in Age-Related Macular Degeneration
Robert J. Klein,Caroline J. Zeiss,Emily Y. Chew,Jen-yue Tsai,Richard S. Sackler,Chad Haynes,A. K. Henning,John Paul SanGiovanni,Shrikant Mane,Susan T. Mayne,Michael B. Bracken,Frederick L. Ferris,Jurg Ott,Colin J. Barnstable,Josephine Hoh +14 more
TL;DR: A genome-wide screen for polymorphisms associated with age-related macular degeneration revealed a polymorphism in linkage disequilibrium with the risk allele representing a tyrosine-histidine change at amino acid 402 in the complement factor H gene.
Journal ArticleDOI
Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration
David M. Brown,Peter K. Kaiser,Mark Michels,Gisèle Soubrane,Jeffrey S. Heier,Robert Y. Kim,Judy P. Sy,Susan Schneider +7 more
TL;DR: Ranibizumab was superior to verteporfin as intravitreal treatment of predominantly classic neovascular age-related macular degeneration, with low rates of serious ocular adverse events and treatment improved visual acuity on average at 1 year.
Journal ArticleDOI
Complement factor H variant increases the risk of age-related macular degeneration.
Jonathan L. Haines,Michael A. Hauser,Silke Schmidt,William K. Scott,Lana M. Olson,Paul Gallins,Kylee L. Spencer,Shu Ying Kwan,Maher A. Noureddine,John R. Gilbert,Nathalie Schnetz-Boutaud,Anita Agarwal,Eric A. Postel,Margaret A. Pericak-Vance +13 more
TL;DR: DNA resequencing of the complement factor H gene within this haplotype revealed a common coding variant that significantly increases the risk for AMD with odds ratios between 2.45 and 5.57, which likely explains ∼43% of AMD in older adults.
Related Papers (5)
A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration
Gregory S. Hageman,Don H. Anderson,Lincoln V. Johnson,Lisa S. Hancox,Andrew J Taiber,Lisa I. Hardisty,Jill L. Hageman,Heather Stockman,James D. Borchardt,Karen M. Gehrs,Richard J.H. Smith,Giuliana Silvestri,Stephen R. Russell,Caroline C W Klaver,Irene Barbazetto,Stanley Chang,Lawrence A. Yannuzzi,Gaetano R. Barile,John C. Merriam,R. Theodore Smith,Adam Olsh,Julie Bergeron,Jana Zernant,Joanna E. Merriam,Bert Gold,Michael Dean,Rando Allikmets +26 more